Department of Oncology, Division of Radiation Oncology, McGill University Health Centre, Montreal, Quebec.
The combined use of radiation therapy (RT) and androgen deprivation for patients with localized high-risk prostate cancer is commonly accepted as the standard treatment among uro-oncologists. Preclinical studies have provided rationale for the use of this combination. Additionally, results of phase 3 studies using conventional doses of RT have supported the combined approach. Other phase 3 studies have also shown a benefit for using higher doses of RT; however, the role of androgen deprivation in this context is not clear. The optimal duration of the androgen deprivation, in both the neoadjuvant and adjuvant setting, is still under investigation. This article critically reviews the data on the use of RT combined with androgen deprivation for the treatment of high-risk prostate cancer with emphasis on the results of phase 3 trials.
Written by:
Dal Pra A, Cury FL, Souhami L. Are you the author?
Reference: Int Braz J Urol. 2011 Mar-Apr;37(2):161-79.
doi: 10.1590/S1677-55382011000200003
PubMed Abstract
PMID: 21557833
UroToday.com Prostate Cancer Section
